Q-omics provides the consensus-scored CAPZA1P5 profile across patient tissues and cancer cell-line models. CAPZA1P5 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CAPZA1P5 is differentially expressed in 2, with the highest sampling consensus in THCA. Additionally, CAPZA1P5 RNA expression shows 6,128 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, THCA, and STAD as cancer lineages where CAPZA1P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CAPZA1P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CAPZA1P5 survival associations across molecular data types. CAPZA1P5 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CAPZA1P5 RNA expression–survival associations across cancer types. High CAPZA1P5 expression shows unfavorable associations in MESO, COAD, SKCM, LIHC, THCA and ESCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CAPZA1P5 RNA expression.
This table summarizes CAPZA1P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CAPZA1P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CAPZA1P5 shows lower tumor expression in THCA and KIRC. The THCA box plot shows higher CAPZA1P5 RNA expression in normal versus tumor tissue (log2 FC = −0.027, t-test p = .005).
This table shows molecular features associated with CAPZA1P5 in patient tissues and cancer cell lines. In patient samples, CAPZA1P5 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
